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Abstract
Background: Microglia are major players in the pathogenesis of multiple sclerosis (MS) and may play a dual role in
disease progression. The activation status of microglia in vivo is highly dynamic and occurs as a continuum, with
the pro-inflammatory and anti-inflammatory phenotypes on either end of this spectrum. Little is known about in
vivo dynamics of microglia phenotypes in MS due to the lack of diagnostic tools. Positron emission tomography
(PET) imaging is a powerful non-invasive technique that allows real-time imaging of microglia activation phenotypes in
the central nervous system, depending on the availability of selective PET tracers. Our objective is to investigate and
characterize the expression of the purinergic receptors P2Y12R and P2X7R as potential targets for PET tracer development
and subsequent PET imaging in order to evaluate the dynamics of microglia status in vivo.
Methods: We used immunohistochemical analysis to explore the expression of P2Y12R and P2X7R in experimental
autoimmune encephalomyelitis (EAE) post-mortem tissues and different stages of well-characterized MS lesions. We
evaluated by quantitative real-time polymerase chain reaction the expression of P2Y12R and P2X7R in human polarized
microglia, and we performed autoradiography binding assay with radiolabeled P2Y12R and P2X7R antagonists using MS
and rat EAE tissues.
Results: Here, we demonstrate that P2X7R is associated with a pro-inflammatory phenotype of human microglia in vitro,
and is highly expressed in microglia in MS lesions as well as during the peak of EAE. In contrast, P2Y12R was associated
with an anti-inflammatory phenotype in human microglia in vitro and was expressed at lower levels in active
inflammatory MS lesions compared to normal-appearing white matter (NAWM) and similarly in EAE, while its
expression increased in the remission phase of EAE. Binding of radiolabeled tracers specific for P2Y12R and P2X7R
on ex vivo tissues validated the value of these receptors as PET imaging targets for microglia phenotypes in vivo.
Conclusion: Our results suggest that P2Y12R and P2X7R are excellent targets for PET imaging to discriminate
distinct microglia phenotypes in MS. Ultimately, this may provide insight into the role of microglia in disease
progression and monitor novel treatment strategies to alter microglia phenotype.
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Background
Multiple sclerosis (MS) is an inflammatory autoimmune
disease of the central nervous system (CNS) character-
ized by massive immune cell infiltration, glia activation,
severe demyelination, and neurodegeneration [1]. In the
disease progression, microglia play a profound role
through the secretion of pro-inflammatory mediators,
myelin phagocytosis, and antigen presentation. However,
recent insights indicate that in MS, microglia also exert
protective and anti-inflammatory effects by the produc-
tion of neuroprotective factors, thereby playing a role in
disease resolution [2–4]. Microglia are highly dynamic
cells that are constantly sensing their microenvironment
[5, 6]. The activation status of microglia in vivo is highly
dynamic and occurs as a continuum, with pro-
inflammatory cytotoxic microglia on one end of the
spectrum and anti-inflammatory, repair promoting
microglia on the other side [7, 8]. In the experimental
autoimmune encephalomyelitis (EAE) model, the well-
established animal model for MS, it has been shown that
pro-inflammatory microglia and macrophages contribute
to disease development by secreting inflammatory cyto-
kines and recruitment of cytotoxic T cells into the CNS
[9, 10]. On the other hand, anti-inflammatory microglia
and macrophages are predominant in the recovery phase
where they contribute to phagocytosis of myelin debris
and associated axonal regeneration [11, 12]. This pro-
tective role was corroborated by several studies showing
that injection of macrophages polarized towards a more
anti-inflammatory phenotype inhibited or ameliorated
EAE associated clinical signs in mice [13, 14].
The role of microglia in MS pathology and its contribu-
tion to disease progression remains unclear. The develop-
ment of new treatments for MS relies heavily on
improved understanding of neuroinflammation and the
role of activated microglia in the disease evolution. Many
questions are still pending concerning the role of pro- and
anti-inflammatory microglia in MS and how immuno-
modulatory therapy affects the state of microglia activa-
tion. Getting insights into the molecular dynamics and
polarization of activated microglia in vivo is only possible
through a highly sensitive and non-invasive imaging tech-
nique as positron emission tomography (PET). Current
developments in PET imaging of activated microglia are
centered around targeting translocator protein (TSPO), a
mitochondrial protein overexpressed in activated micro-
glia [15]. TSPO imaging provided valuable information in
detecting the presence of active neuroinflammation, but
failed to discriminate between pro- and anti-inflammatory
states of microglia and was subjected to significant level of
polymorphism between different subjects which limited
its utility [16]. Hence, there is an urgent need for new
PET imaging tools and new target receptors for imaging
activated microglia in neuroinflammation.
Ionotropic and metabotropic receptors P2X7R and
P2Y12R, respectively, are expressed on microglia and are
involved in microglia response to brain tissue damage and
neurodegeneration [9]. P2X7R is a purinergic, ATP bind-
ing, receptor expressed on immune cells such as mono-
cytes, macrophages, and microglia [17]. In addition,
P2X7R plays an important role in activating the inflamma-
some and subsequent release of IL-1β [18–20]. P2Y12R
belong to the family of G protein-coupled receptor, and
studies have shown that P2Y12R is only expressed on
microglia and not peripheral or infiltrated macrophages in
the brain [21, 22].
In this study, we investigated P2X7R and P2Y12R re-
ceptors as potential targets for PET imaging of pro- and
anti-inflammatory microglia in well-characterized MS
tissue samples and the EAE model.
Our data indicate that P2X7R and P2Y12R are promis-
ing selective targets for PET imaging of microglia phe-
notypes in vivo. Visualization of microglia activation and
the dynamics of their activation status will provide valu-
able insights into the status and role of microglia during
MS disease progression. Furthermore, it may contribute
to a better understanding of the relation between micro-
glia activation status and neurodegeneration, and in the
development and evaluation of new immunomodulatory
and disease-modifying therapies.
Methods
Reagents
Chemicals were obtained from commercial sources
and used without further purification. Solvents were
purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands), MERCK (Darmstadt, Germany) and
Biosolve (Valkenswaard, The Netherlands) and used as
received unless stated otherwise. Tetrahydrofuran
(THF) was first distilled from LiAlH4 and then stored
on 3 Å molecular sieves. [3H]methyl nosylate stock
solution (717 MBq/mL in toluene, molar radioactivity
of 3.08 GBq.μmol−1) was obtained from Novandi
Chemistry AB (Södertälje, Sweden) and dried at 60 °C
under an argon flow prior to use.
Radioligand synthesis
[3H]A-740003
[3H]A-740003 was synthesized in a similar manner as
previously described for [11C]A-740003 [23]. Briefly, des-
methyl precursor was reacted with [3H]methyl nosylate
in the presence of tetrabutylammonium hydroxide for
16 h at room temperature. HPLC purification was per-
formed on a Reprospher 100 C18-DE (50 × 8 mm, 5 μm)
column (Dr. Maisch GmbH, Ammerbuch, Germany)
using MeCN/H2O/diisopropylamine (22:78:0.1, v/v/v) as
eluent at a flow rate of 3 mL.min−1. Fractions containing
product (tR = 16 min) were collected and formulated in
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1.5 mL 96% EtOH. Radioactivity concentration
(10.9 kBq.μL−1) was determined by liquid scintillation
counting (LSC) (LKB/Wallac 1219 Rackbeta, Mount
Waverley, Australia) using 5 mL of Optiphase “Highsafe
3” scintillation liquid (PerkinElmer, Waltham, MA,
USA). The identity of the product was confirmed with
analytical HPLC by coinjection of the product and non-
labeled A-740003 (tR = 10 min), and the (radiochemical)
purity was > 99%. Analytical isocratic HPLC was per-
formed on an Xbridge C18 5 μm (100 × 4.6 mm) column
(Waters, Milford, MA, USA) using MeCN/H2O (30:70,
v/v) as eluent at a flow rate of 1 mL.min−1.
[11C]P2Y12R antagonist
Ethyl 6-(3-(3-((5-chlorothiophen-2-yl)sulphonyl)[11C]urei-
do)azetidin-1-yl)-5-cyano-2-methylnicotinate, as well as
precursors ethyl 6-(3-aminoazetidin-1-yl)-5-cyano-2-
methylnicotinate and 5-chlorothiophene-2-sulphonyl
azide were synthesized as previously described [24]. Here-
after, we will refer to this antagonist as [11C]P2Y12R-ant.
Briefly, [11C]CO was transferred to a vial containing a
solution of the precursors, chloro(1,5-cyclooctadiene)rho-
dium(I) dimer and triphenylphosphine in dry THF. The
reaction mixture was heated at 100 °C for 5 min, and sub-
sequently, the excess of the azide precursor was quenched,
simultaneously evaporating most of THF. After semi-
preparative HPLC purification on an Altima C18 5 μm
(250 × 10 mm) column (Grace, Columbia, MD, USA)
using MeCN/H2O/TFA (55:45:0.1, v/v/v) as eluent at a
flow rate of 4 mL.min-1, ethyl 6-(3-(3-((5-chlorothiophen-
2-yl)sulphonyl)[11C]ureido)azetidin-1-yl)-5-cyano-2-
methylnicotinate (tR = 16 min) was formulated in 1 mL of
EtOH and diluted with 5 mL of 7.09 mM NaH2PO4 in
saline. The tracer was obtained in a decay-corrected radio-
chemical yield (RCY) of 6 ± 2% (n = 2; calculated from
[11C]CO2 at end of bombardment) with a radiochemical
purity > 99%, a molar radioactivity of 37 ± 4 GBq.μmol−1
(n = 2). The identity of the product was confirmed with
analytical HPLC on a Platinum C18 5 μm (250 × 4.6 mm)
column (Grace, Columbia, MD, USA) using MeCN/H2O/
trifluoroacetic acid (TFA) (45:55:0.1, v/v/v) as eluent at a
flow rate of 1 mL.min−1 by coinjection of the product and
non-labeled reference compound (tR = 12 min).
Human brain tissue
Brain tissue from three controls and eight MS patients
were used in this study. Patient details are presented in
Additional file 1: Table S1. Brain tissue samples were
obtained from the Netherlands Brain Bank (coordinator
Dr. Huitinga, Amsterdam, The Netherlands). The
Netherlands Brain Bank received permission to perform
autopsies for the use of tissue and for access to medical re-
cords for research purposes from the Ethical Committee
of the VU University Medical Center, Amsterdam, The
Netherlands. All patients and controls, or their next of
kin, had given informed consent for autopsy and use of
brain tissue for research purposes.
EAE model
We used EAE tissues acquired from an independent study
performed in our laboratory and the acute experimental
autoimmune encephalomyelitis (EAE) was induced as
follows. Eight- to 11-week-old male Lewis rats (200 g) ob-
tained from Harlan (Zeist, The Netherlands), as described
before [25]. Rats were injected s.c. with 20 μg synthetic
myelin basic protein 63–88 peptide, 500 μg Mycobacter-
ium tuberculosis type 37HRa (Difco, Detroit, MI, USA),
and 50 μl complete Freund’s adjuvant (CFA) (Difco) sup-
plemented with PBS to reach a volume of 100 μl. Rats
were examined daily (weight and clinical disease) and
graded on a scale from 1 to 5 for neurological signs. Clin-
ical disease in EAE animals was apparent around day 10
post-immunization with a maximum clinical score be-
tween days 14 and 15. Animals were housed under stand-
ard laboratory conditions with water and food ad libitum.
CFA-immunized animals were used as a control. Animals
were sacrificed at day 14 dpi (peak of the disease) and day
20 dpi (recovery phase, end of clinical signs).
Immunohistochemistry
For human tissue staining, air-dried frozen sections
(5 μm) were fixed with acetone (10 min at RT). For
single immunohistochemistry staining of proteolipid
protein (PLP), MHC-II, purinergic receptor P2X7R, and
P2Y12R, we used the protocol described previously by
Vogel et al. [4] using Envision-HRP (Dako) and 3,3′-di-
aminobenzidine (Dako) as detection method.
For immunofluorescence staining on human tissue,
sections were fixed with acetone then blocked for non-
specific binding with goat serum (10%) for 20 min at
RT. Sections were then incubated with the primary anti-
body (anti-P2Y12R or anti-P2X7R) in PBS/1% serum
overnight at 4 °C. Sections were then washed with PBS
three times for 5 min and incubated with fluorescence-
labeled secondary antibody (1/400) in PBS/1% serum or
for 1 h at RT. Sections were then washed three times for
5 min with PBS and blocked with mouse serum (10%)
for 20 min at RT followed by incubation with anti-
MHC-II or anti-CD31 or anti-GFAP antibody in PBS/1%
BSA for 1 h at RT. After three times of washes for
5 min, a fluorescently labeled secondary antibody was
added in PBS/1% BSA for 1 h at room temperature.
Nuclei were stained with Hoechst (1/1000) for 1 min in
the dark. After a final wash for three times for 5 min
with PBS, sections were mounted with coverslips using
aqueous mounting media Mowiol.
For rat tissue immunofluorescence double staining,
air-dried frozen sections (7 μm) were used. Tissues from
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three different EAE animals at day 14 post-immunization
and three different EAE animals at day 20 post-
immunization, and three CFA control rat brains were
used. Sections were fixed with acetone for 10 min at RT
and blocked for non-specific binding using BSA 2%. Sec-
tions were then incubated with a mix of both primary
antibodies overnight at 4 °C or 1 h at room temperature.
Sections were then washed three times in PBS/0.05%
Tween-20 and then incubated with fluorescently labeled
secondary antibodies and DAPI (1/1000) for nuclear stain-
ing for 1 h at RT. Sections were then washed three times
for 5 min with PBS/0.05% Tween-20. Sections were
mounted with coverslips using aqueous mounting media
Mowiol.
Fluorescence images were acquired using Leica
DM6000 microscope equipped with a motorized stage.
Whole-slide low-zoom images were acquired using ×10
objective and merged by tile stitching to get the final
image. For fluorescence quantification and comparison,
sections were stained in a single run and images were
collected in a single session with the same exposure time
between different areas and different slides. Bright field
images were acquired on a Zeiss bright field microscope
equipped with a colored camera. Images were analyzed
using Leica LAS AF or Zen 2012 software. The list of
antibodies used for immunohistochemistry and im-
munofluorescence are described in Additional file 1:
Table S3.
Human microglia isolation
Human microglia isolation and preparation was per-
formed as described elsewhere [3]. In brief, 5 to 10 g of
brain white matter was obtained at autopsy, and micro-
glia isolation procedure was performed within 4 to 24 h.
Single-cell suspension was prepared using 0.05% trypsin
(Sigma, St Louis, MO). Cells were then filtered through
a 100-μm nylon mesh (BD Bioscience, Durham, NC)
and centrifuged, and the pellet is resuspended in a gradi-
ent buffer (3.56 g/L Na2HPO4·2H2O, 0.78 g/L NaH2-
PO4·H2O, 8 g/L NaCl, 4 g/L KCl, 2 g/L d-(+)-glucose,
and 2 g/L BSA, pH 7.4) and centrifuged for 35 min at
1200×g. The cell debri-myelin layer was removed. The
cell pellet was treated with red blood cell lysis buffer
(8.3 g/L NH4CL and 1 g/L KHCO3, pH 7.4) for 10 min
at 4 °C. Cells were then suspended and cultured in
DMEM/Ham nutrient mixture F10 (1:1), 1% penicillin-
streptomycin-glutamine, and 25 ng/mL granulocyte-
macrophage colony-stimulating factor (GM-CSF is only
added for the first 2 days). After 7 days, microglia were
polarized into a pro-inflammatory status by priming with
recombinant IFN-γ (1 × 103 U/mL) (U-Cytech, Utrecht,
The Netherlands) for 24 h, followed by addition of
Escherichia coli LPS (10 ng/mL) (LPS-EB ultrapure;
Invitrogen, San Diego, CA) to the medium for 24 h. To
induce anti-inflammatory microglia, cells were stimu-
lated with IL-4 (10 ng/mL) (Immunotools, Friesoythe,
Germany) for 48 h. Untreated cells were referred to as
M0.
RNA isolation and real-time quantitative polymerase
chain reaction
All oligonucleotides were synthesized by Ocimum Biosolu-
tions (Ocimum Biosolutions, Ijsselstein, The Netherlands).
RNA was isolated using triazol. cDNA was synthesized with
the Reverse Transcription System kit (Promega, Madison,
WI, USA) following manufacturer’s guidelines as described
previously [26]. QPCR reactions were performed on an
Applied Biosystems ViiA 7 machine with the SYBR Green
method (Applied Biosystems, Carlsbad, CA, USA).
Obtained expression levels of transcripts were normalized
to GAPDH and PolRF2 expression levels. Here, we report
only the results normalized to GAPDH as we did not
observe any difference of normalized data between
GAPDH and PolRF2. All primer sequences are listed
in Additional file 1: Table S2.
Western blot
Cells were lysed with RIPA lysis buffer containing prote-
ase inhibitors for 1 h on ice. The cells were then centri-
fuged at 14,500 rpm for 15 min, the pellet was
discarded, and the supernatant was collected. Electro-
phoresis was performed under denaturating conditions
on 10% SDS polyacrylamide gel. The proteins were
transferred to a nitrocellulose membrane. Blots were sat-
urated in Odyssey buffer/PBS (1:1) for 1 h at RT. The
blots were incubated with primary antibodies Rabbit
anti-human P2X7R (Alomone, Jerusalem BioPark (JBP),
Israel), or Rabbit anti-human P2Y12R (Ananspec, LIEGE
Science Park, Belgium) in Odyssey buffer/PBS (1:1) +
Tween-20 (0.1%) overnight at 4 °C followed by fluores-
cently labeled secondary antibody (Odyssey) in Odyssey
buffer/PBS (1:1) + Tween-20 (0.1%) for 1 h at room
temperature. Blots were imaged using Odyssey imager.
Blot were then washed and stained with goat anti-
human β-actin (Santa Cruz, Heidelberg, Germany) anti-
body following the same procedure as above. Western
blot relative quantification was realized by calculating
the ratio of the integrated intensity of the band of the
protein of interest over the integrated intensity of the
band of β-actin.
Autoradiography
For autoradiography tissues from three non-neurological
controls, three active, two chronic active, and three
chronic inactive MS lesions, and from three different
EAE animals at day 14 post-immunization and three dif-
ferent EAE animals at day 20 post-immunization, and
three CFA control rat brains were used. Tissue
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cryosections (20 μm) of acute EAE and human MS were
mounted on glass slides, air dried and stored at −80 °C
until use. Sections were washed in assay buffer (50 mM
Tris-HCl, pH 7.4) for three times 5 min and then dried
under an air flow. Sections were incubated with
[11C]P2Y12R-ant (10 nM) for 30 min at room
temperature, or incubated with [3H]A740003 for 1 h and
30 min at room temperature. Sections were then washed
three times for 90 s with Tris-HCl (50 mM, pH 7.4) and
dipped twice in deionized water. Sections were dried
under an air flow and exposed to phosphor screen BAS-
IP TR 2025 (for tritum-labeled tracer) or phosphor
screen BAS-IP SR 2025 (for carbon-11-labeled tracer)
(General Electric, Eindhoven The Netherlands) for 1 h
for [11C]P2Y12R or 48 h for [3H]A740003. Phosphor
screen were then imaged using Typhoon FLA 7000
imager (General Electric, Eindhoven, The Netherlands).
The intensity of the signal was quantified using image
Quant software (General Electric, Eindhoven, The
Netherlands). Three independent experiments were
performed.
Statistical analysis
All data are presented as mean ± SD. Groups were com-
pared using the two-tailed Student t test (normal), and
Mann-Whitney (non-normal) and analysis were done
with Graphpad prism 5 (San Diego, CA, USA). p values
of less than 0.05 were considered statistically significant.
Results
Dynamic of expression of P2Y12R and P2X7R in human
polarized microglia
To investigate the regulation of P2Y12R and P2X7R ex-
pression, human microglia were freshly isolated from 10
different adult post-mortem brains, cultured for 7 days
and then polarized into an inflammatory phenotype with
IFN-γ/LPS or anti-inflammatory phenotype with IL-4 as
described previously [3] (Additional file 1: Figure S1).
Expression levels of P2Y12R, P2X7R, and TSPO were
measured using quantitative PCR. P2Y12R was signifi-
cantly downregulated in inflammatory polarized micro-
glia compared to non-stimulated microglia (fourfolds
lower, p < 0.001). In anti-inflammatory polarized micro-
glia, the expression of P2Y12R was strongly increased
compared to non-stimulated microglia (threefolds
higher, p < 0.01) and pro-inflammatory polarized micro-
glia (12-folds higher, p < 0.001) (Fig. 1a).
P2X7R expression revealed an opposite expression pat-
tern with a significant increase in pro-inflammatory
microglia (fivefolds higher, p < 0.01) compared to non-
stimulated microglia and anti-inflammatory stimulated
microglia (fivefolds higher, p < 0.01). No significant
change was observed in anti-inflammatory microglia,
which indicates a strong association of P2X7R with a
pro-inflammatory microglia phenotype (Fig. 1b). The in-
creased expression of P2X7R in pro-inflammatory
microglia and P2Y12R in anti-inflammatory microglia
was also observed at the protein level as shown by west-
ern blot from the same donors (Fig. 1d, e). Protein level
was only evaluated in two donors due to the low amount
of microglia cells obtained from the isolations which
makes it challenging to have enough protein for western
blot analysis. We next investigated the expression of
TSPO as this marker is considered to be the state of art
for PET imaging of activated microglia. TSPO was highly
expressed in pro-inflammatory microglia (1.5-folds
higher, p < 0.05), albeit less pronounced compared to
P2X7R (1.5-folds vs fivefolds, respectively). In anti-
inflammatory microglia, no significant change of TSPO
expression was observed compared to non-stimulated
microglia (Fig. 1c).
Expression of P2Y12R and P2X7R in multiple sclerosis
lesions
In order to investigate P2Y12R and P2X7R as targets for
imaging microglia phenotype in MS, we analyzed their
expression in white matter samples from three non-
neurological controls, three active, two chronic active,
and three chronic inactive MS lesions (control, Fig. 2a–
d; active, Fig. 2e–l; chronic active, Fig. 2m–p, chronic in-
active, Fig. 2q–t; Additional file 1: Figure S2-5). P2X7R
and P2Y12R were expressed on ramified cells in control
brain and normal-appearing white matter (NAWM) that
were identified as microglia by their colocalization with
MHC-II (Fig. 3). In inflamed MS lesions, P2X7R and
P2Y12R are expressed on activated microglia character-
ized by their round shape and high MHC-II expression
(Figs. 2 and 3; Additional file 1: Figure S2-S5). GFAP-
(marking activated astrocytes) and CD31- (marking
endothelial cells) positive cells in MS lesion, NAWM, or
control tissue did not express P2X7R or P2Y12R
(Additional file 1: Figure S7-10).
P2X7R and P2Y12R expression on microglia is affected
by their activated state. To compare the change of ex-
pression of P2X7R and P2Y12R between ramified and
activated microglia, we performed colocalization studies
with MHC-II in active and chronic active MS lesions.
P2X7R was more robustly expressed on activated micro-
glia in active lesions and on microglia in the active rim
of the chronic active lesions compared to microglia in
the NAWM (Fig. 3m–x; Additional file 1: Figure S11). In
contrast, P2Y12R immunolabeling showed a gradual de-
crease of expression on microglia from the NAWM to-
wards the center of the active lesion (Fig. 3a–l).
Interestingly, at the border of the active lesion, we
observe a mixed population of activated microglia ex-
pressing either high or low levels of P2Y12R; the same
pattern was also observed in activated microglia in the
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rim of the chronic active lesions (Additional file 1:
Figure S12).
P2Y12R and P2X7R expression on microglia in human MS
lesions
We observe that P2X7R and P2Y12R are differentially
expressed within MS active lesions. In order to investi-
gate the dynamic of expression of P2X7R and P2Y12R,
we compared their respective change of expression on
ramified microglia in the NAWM and activated micro-
glia in MS lesions. Enhanced expression of P2X7R on
activated microglia in the MS lesion is accompanied by a
decrease in microglial P2Y12R expression on the same
cells (Fig. 4a, b). To further evaluate the relation
between the expression of P2Y12R and P2X7R, we quan-
tified their expression by drawing regions of interest
(ROIs) around microglia in the NAWM and MS lesion.
When comparing the microglia at the ramified less acti-
vated state to the highly activated state, we detected that
in the majority of microglia an increase of expression of
P2X7R coincides with a decrease of P2Y12R expression
(Fig. 4c, d). We also observed a small population of acti-
vated microglia that shows an increase of P2X7R expres-
sion and no decrease in P2Y12R expression; these cells
were mostly located at the border of the lesion.
Expression of P2Y12R and P2X7R in acute EAE lesions
To investigate whether the change of expression of
P2Y12R and P2X7R that we observed in post-mortem
human MS tissue also occurs in EAE, a well-established
animal model of MS, we performed immunohistochemis-
try on tissues from acute EAE induced in Lewis rats. We
used cerebellum and brain stem tissue sections where the
majority of neuroinflammation and immune cell infiltra-
tion occurs in this particular model. Tissues were
collected from EAE animals at the peak of the disease
(day 14 post-immunization) and in the recovery phase
(day 20 post-immunization). Tissues from animals immu-
nized with complete Freund’s adjuvant (CFA) were used
as control. Microglia were stained with anti-CD11b, and
sections were analyzed by differentiating a highly inflamed
and a less inflamed area based on the CD11b staining.
Fig. 1 P2Y12R, P2X7R, and TSPO expression in non-stimulated (non-sti), pro-inflammatory (pro-inf), and anti-inflammatory (anti-inf) polarized hu-
man adult microglia. Quantitative PCR analysis and western blot were performed on mRNA and cell lysate collected from non-stimulated, LPS-
stimulated pro-inflammatory, and IL-4-stimulated anti-inflammatory human cultured microglia. Expression level of P2Y12R (a), P2X7R (b), and TSPO
(c) was evaluated. P2X7R and TSPO were significantly upregulated in pro-inflammatory microglia, and P2Y12R was significantly upregulated in anti-
inflammatory microglia (n= 10 donors; each sample is done in duplicate). Representative western blot (d) and quantification (e) of P2Y12R and P2X7R pro-
tein expression in non-stimulated, pro-inflammatory, and anti-inflammatory human microglia (n= 2 donors). Error bars represent SD. Each sample was done
in duplicate. (one asterisk) p< 0.05, (two asterisks) p< 0.01, (three asterisks) p< 0.001
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We first investigated the expression of P2X7R and
P2Y12R in control animals. P2Y12R immunoreactivity
localized with CD11b-positive microglia in control
brain tissue (Additional file 1: Figure S13). No P2X7R
expression was detected in control brain tissue, which
may be due to the low expression of P2X7R and/or
the low sensitivity of the antibody (Additional file 1:
Figure S16).
At the peak of the disease, we observed a marked de-
crease of P2Y12R on CD11b-positive cells in the highly
inflamed area. Quantification of the P2Y12R fluores-
cence signal revealed a significant reduction of the stain-
ing in the inflamed area compared to the less inflamed
area (Fig. 5a–d). In EAE, at the end of the recovery
phase, P2Y12R is markedly expressed on CD11b-positive
microglia compared to microglia in the less inflamed
Fig. 2 Expression of P2Y12R and P2X7R in controls, MS active, chronic active, and inactive lesions. PLP and MHC-II staining in different MS lesions
and control (a, b, e, f, i, j, m, n, q, r). P2Y12R and P2X7R expression on ramified microglia in control human brain tissue (c, d). P2Y12R expression
in MS active lesion (g, k), chronic active lesion (o), and chronic inactive lesion (s). P2X7R expression in MS active lesion (h, l), chronic active lesion
(p), and chronic inactive lesion (t). The images were taken at the middle of the lesion for active sections and at the rim of the lesion for chronic
active sections. Scale bar is 20 μm when not specified
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Fig. 3 (See legend on next page.)
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area (Fig. 6a, b). The quantification of the P2Y12R
expression showed a significant increase of the P2Y12R
expression in the inflamed area compared to the less in-
flamed area (Fig. 6c, d). Infiltrating monocyte-derived
macrophages (ED1-positive) in the perivascular area did
not express P2Y12R (Additional file 1: Figure S14).
P2X7R was highly expressed on CD11b-positive cells
in the EAE tissue at the peak of the disease and at the
end of the recovery phase. The expression of P2X7R on
activated microglia in the inflamed area was higher com-
pared to the ramified microglia in the less inflamed area
(Fig. 7a, b).
(See figure on previous page.)
Fig. 3 Expression of P2Y12R and P2X7R on MHC-II-positive cells in MS active lesion. Low-zoom images showing P2Y12R and MHC-II double staining in MS
active lesion (a, e, i); asterisk indicates the center of the lesion. High-magnification images of P2Y12R and MHC-II double staining taken at the center of the
lesion (b, f, j), the border of the lesion (c, g, k), and the NAWM (d, h, l). Low-zoom images showing P2X7R and MHC-II double staining in MS active lesion
(m, q, u). High-magnification images of P2X7R and MHC-II double staining taken at the center of the lesion (n, r, v), the border of the lesion (o, s, w), and
the NAWM (p, t, x). All images were acquired in the same session using same exposure time between different areas to allow comparison. Blue is nuclear
staining with Hoechst. Scale bar is 25 μm when not specified
Fig. 4 Expression of P2Y12R and P2X7R on microglia in NAWM and human MS active lesion. Double staining showing the expression of P2Y12R
and P2X7R in NAWM (a) and MS active lesion (b). Images were collected from the same section with the same exposure time between different
areas to allow comparison. Scatter plot showing quantification of P2Y12R and P2X7R fluorescence mean intensity (MFI) on microglia in NAWM
(179 cells quantified) (c), and active MS lesion (241 cells quantified) (d). Each dot represents a single cell. All images for quantification were collected
from a single section and were acquired in a single imaging session with the same exposure time. Regions of interest (ROIs) were drawn manually
delineating each cell using Leica LAS AF software
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Fig. 5 P2Y12R expression is downregulated on activated microglia in EAE at the peak of the disease. P2Y12R and CD11b double staining on EAE
tissues from the peak of the disease showing a highly infiltrated and inflamed area, and a less inflamed area (a). Higher magnification images of
P2Y12R and CD11b staining showing a reduction of P2Y12R expression on microglia in the high inflamed area compared the less inflamed area
(b). Fluorescence quantification of CD11b (c) and P2Y12R (d) showing a significant increase in CD11b expression and a significant decrease of
P2Y12R expression in the highly inflamed area compared to the less inflamed area. Each circle and square represents one drawn region of interest (ROI)
and represents tissues from two different rats. Different groups were compared using the Student t test, (one asterisk) p< 0.05, (three asterisks) p < 0.0001.
Blue is nuclear staining with DAPI
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Binding of P2Y12R and P2X7R radiolabeled tracers on MS
and acute EAE tissue
To investigate the binding of PET tracers and their abil-
ity to predict and follow the change of P2Y12R and
P2X7R expression, we performed autoradiography bind-
ing experiment using a carbon-11-labeled specific
P2Y12R tracer ([11C]P2Y12R-ant) and tritium-labeled
P2X7R-specific tracer ([3H]A-740003) for binding to
EAE and human MS post-mortem tissues. For these
binding experiments, we used sections from the same
human MS and EAE tissues blocks as for the immuno-
staining experiments. In tissue from acute EAE animals,
we observed a significant decrease of binding of the
[11C]P2Y12R-ant tracer at the peak of the disease com-
pared to the control that increases back in the recovery
phase. P2X7R tracer, [3H]A-740003, showed a significant
increase of binding to EAE tissues from the peak of the
disease compared to control. The binding of [3H]A-
Fig. 6 P2Y12R expression is upregulated on activated microglia in EAE in the recovery phase. P2Y12R and CD11b double staining on EAE tissues
from the recovery phase showing a highly infiltrated and inflamed area, and a less inflamed area. Arrow head shows high P2Y12R staining on
CD11b positive cells (a). Higher magnification images of P2Y12R and CD11b staining showing an increase of P2Y12R expression on microglia in
the high inflamed area compared the less inflamed area (b). Fluorescence quantification of CD11b (c) and P2Y12R (d) showing a significant increase in
CD11b and P2Y12R expression in the highly inflamed area compared to the less inflamed area. Each circle and square represents one drawn region of
interest (ROI) and represents tissues from three different rats. Different groups were compared using student t-test, (one asterisk) p< 0.05, (three asterisks)
p< 0.0001. Blue is nuclear staining with DAPI
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740003 slightly decreased in the recovery phase
(Fig. 8a–c). In human MS tissues, the binding of
[11C]P2Y12R-ant tracer was significantly decreased in
all types of MS lesions (active, chronic active, and
chronic inactive) compared to control (Fig. 8d, f ).
The binding of P2X7R tracer [3H]A-740003 was sig-
nificantly increased only in the MS active lesion while
there was a slight non-significant increase in chronic
active lesions and a decrease in the chronic inactive
lesions compared to control (Fig. 8e, f ). We also per-
formed blocking studies and post-autoradiography
immunostaining; our data showed that the binding of
both tracers is specific and matches the antibody
staining (Additional file 1: Figure S17-19). The bind-
ing of the P2X7R and P2Y12R tracers correlated with
our immunohistochemistry results which further val-
idate these receptors as potential targets for use in
PET imaging of activated microglia.
Fig. 7 P2X7R expression in rat EAE at the peak of the disease and in the recovery phase. P2X7R and CD11b double staining on EAE tissue from
the peak of the disease (a) and the recovery phase (b). Blue is nuclear staining with DAPI. Scale bar is 25 μm
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Discussion
Our data show that P2X7R and P2Y12R can be used for
PET tracer development and have the potential to dis-
criminate between pro- and anti-inflammatory microglia
in vivo by PET imaging upon successful development of
a PET tracer. This may help in obtaining insights into
the role of microglia in disease progression and enabling
the development of novel treatment strategies aimed at
altering microglial phenotype in order to promote
neuro-protection. The pathogenesis of MS is complex,
and the role of microglia in the development and resolv-
ing of the disease is still poorly understood mainly due
to the lack of tools to visualize such dynamics. In vitro,
microglia can be polarized into pro-inflammatory or
anti-inflammatory phenotype depending on stimulus,
but in vivo, it has been hypothesized that the microglia
activation is very dynamic and show rather a spectrum
of activation phenotypes with pro- and anti-
inflammatory characteristics on either end of this
spectrum. PET imaging is a non-invasive technique and
the method of choice for imaging neuroinflammation
due to its high sensitivity and quantifiable images. Our
data suggests that purinergic receptors P2X7R and
P2Y12R could be of high value as PET imaging targets
in order to identify a pro- or anti-inflammatory-balanced
microglia environment that may suggests new insights
into disease progression towards worsening or more re-
solving state.
P2X7R is markedly expressed on activated microglia
and infiltrated macrophages in inflamed MS tissue com-
pared to microglia in the NAWM. P2X7R might be acti-
vated by increased levels of ATP that are released during
the inflammatory process and cellular damage that is
prominent in MS active lesions [27]. P2X7R signaling is
also involved in the activation of the inflammasome and
the release of IL-1β by activated microglia that is a main
Fig. 8 Autoradiography on acute rat EAE tissue and human MS tissue using P2Y12R and P2X7R radiotracers. Representative autoradiograms of carbon-
11-labeled P2Y12R-ant on rat control and EAE tissues (a). Representative autoradiograms of tritium-labeled A-740003 (P2X7R specific antagonist) on rat
control and EAE tissues (b). Quantification of binding of [11C]P2Y12R-ant and [3H]A-740003 on rat control and EAE tissues (data presented is the summary
of n= 3 animals per time point and three independent experiments) (c). Representative autoradiograms of [11C]P2Y12R-ant on different human MS lesion
types (d). Representative autoradiograms of tritium-labeled A-740003 (P2X7R specific antagonist) on different human MS lesion types (e). Quantification
of binding of [11C]P2Y12R and [3H]A-740003 on different human MS lesions (data presented is a summary of three independent experiments using three
non-neurological controls, three active, two chronic active, and three chronic inactive MS lesions) (f)
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inflammatory cytokine potentially playing a role in the
MS pathogenesis [28]. The increase in P2X7R receptor
in MS and EAE were reported previously using western
blot analysis on whole brain homogenate [17, 29] and on
microglia/macrophages cells in spinal cord of MS lesion
[30]. Our data suggests that microglial P2X7R immuno-
reactivity correlated with a pro-inflammatory environ-
ment and ongoing neuroinflammation. We also
observed an increase in P2X7R expression on activated
microglia and macrophages at the peak of EAE when the
level of inflammation is at the highest. Surprisingly,
P2X7R is not reduced on activated microglia in the
recovery phase of the EAE. Inflammatory cytokines, i.e.,
IL-17, IFN-γ, TNF-α, are still present in the recovery
phase, but are counter balanced by enhanced levels of
anti-inflammatory cytokines, i.e., IL-4 and IL-10 [31].
This implies that P2X7R expression on microglia is less
regulated by anti-inflammatory stimuli that occur in the
recovery phase in EAE and more responsive to inflam-
matory cytokines.
P2Y12R expression behaved in opposite direction to
P2X7R where the expression was significantly downreg-
ulated on activated microglia in MS lesion compared to
the microglia in the NAWM. In the EAE model at the
peak of the disease, we observe a downregulation of
P2Y12R expression on activated microglia in line with
earlier reports [13, 22, 32]. However, in the recovery
phase of EAE, P2Y12R expression was robustly increased
on activated microglia suggesting that P2Y12R expres-
sion is more regulated by anti-inflammatory cytokines.
In a recent study, Zrzavy et al. reported that a loss of
P2Y12R expression on microglia was observed in both
active MS lesions and the surrounding normal-appearing
white matter (NAWM), suggesting that the chronic in-
flammatory environment in MS may contribute to the
P2Y12R downregulation [32]. Moreover, a higher expres-
sion of P2Y12R was detected on microglia in inactive
lesions where inflammation was subsided which support
our observations about P2Y12R dynamic expression and
sensitivity to cytokine environment.
It is apparent that P2X7R and P2Y12R are differen-
tially expressed when comparing ramified microglia to
activated microglia in MS lesions; an upregulation of
P2X7R is associated with a downregulation of P2Y12R.
Our in vitro data using human microglia polarized into
pro- or anti-inflammatory phenotypes showed similar
responses of P2X7R and P2Y12R expression and corre-
lates with our observation in MS and EAE tissues.
P2Y12R response to pro- or anti-inflammatory stimuli in
isolated microglia was also in accordance with previous
report by Moore et al. [33]. An upregulation of P2Y12R
could occur in the remission phase of MS as it happened
in the recovery phase of the EAE, but the limitation of
post-mortem tissue make it challenging to investigate,
which emphasize the importance of PET imaging for
non-invasive evaluation of such molecular processes. In
addition, the use of M1 and M2 markers to define pro-
inflammatory vs anti-inflammatory microglia phenotypes
has drawbacks as most of the microglia in the MS le-
sions adopt an intermediate M1/M2 phenotype [4]. This
further stress the need of specific PET imaging markers
for the visualization of pro- and anti-inflammatory
microglia status in vivo.
Thorough examination of the immunostainings re-
vealed a profound microglial staining pattern of P2Y12R
expression. No staining was observed in other cell types,
including astrocytes and endothelial cells. These results
are in accordance with other studies showing that the
expression of P2Y12R is restricted to microglia [21, 22,
32]. However, the specificity of P2X7R to microglia is
more controversial. Our results show that P2X7R
expression is restricted to microglia and macrophages in
MS lesion and NAWM which is not fully in line with
other studies showing its expression on other cells in the
brain [34]. We cannot exclude the expression of P2X7R
on other brain cells; however, the expression level may
be lower compared to microglia and the differences in
antibody used or tissue treatment could be the reasons
of the discrepancy.
It is crucial that PET tracers are able to reflect the
changes of expression for these two receptors that we
observe in MS and EAE. Our autoradiography data on
EAE and human MS tissues show that the binding of
the radiolabeled P2X7R and P2Y12R antagonists are in
strong accordance with the antibody staining strength-
ening the rationale of using PET imaging for evaluating
the expression of these two receptors. Our autoradiog-
raphy results give further support to P2X7R and P2Y12R
as valuable targets for PET imaging of pro- and anti-
inflammatory microglia and that the overall change of
expression is significant enough to be detected by in vivo
imaging. Combining PET imaging of these two receptors
may also provide some insight into the pathological type
of lesions in MS as we observe differential tracers bind-
ing in different types of MS lesions.
Altogether, our data shows that P2X7R and P2Y12R
are PET targetable receptors that have the potential of
discriminating between a pro- or anti-inflammatory
microglia environment which may help in predicting a
worsening or more resolving neuroinflammation in MS
and EAE. A possible scenario is that an increase uptake
of P2X7R tracer that is accompanied by a decrease
uptake of P2Y12R may indicate a progressing MS lesion,
while upon immunomodulatory treatment if an increase
of P2Y12R uptake is observed, this may indicate that the
lesion is shifting to more anti-inflammatory environment
and thus indicating a possible resolution of neuroinflam-
mation and treatment efficiency. To that end, we are
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currently finalizing the characterization of specific P2X7R
and P2Y12R PET tracers for the next step of in vivo evalu-
ation of microglia and/or macrophage dynamics in the
EAE model. Moreover, a new P2X7R PET tracer was re-
cently reported and showed promising results in an in
vivo model in which the human P2X7 was overexpressed
through an AAV vector [35]. In addition, the change of
P2X7R and P2Y12R expression on activated microglia is
not restricted to MS and EAE and has been also described
in other neuroinflammatory disease.
Conclusion
The data we present in this study is the first step in the
process that may lead to better understanding of the role
of microglia in MS and other neuroinflammatory diseases.
Furthermore, it may contribute to a better understanding
of the relation between microglia activation status and
neurodegeneration, and in the development of new immu-
nomodulatory and disease-modifying therapies.
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